Other names: MDR1 (multidrug resistance 1) Location: 7q21.2
DNA/RNA

Description
Spans on a 120 kb genomic fragment; separated from MDR3 gene (which is transcribed in the same direction) by only 34 kb of intergenic DNA. 
Protein
Description
The protein is called P-glycoprotein; 170 kDa transmembrane glycoprotein which includes 10-15 kDa of N-term glycosylation; the N-term half of the molecule contains 6 transmembrane domains, followed by a large cytoplasmic domain with an ATP binding site, and then a second section with 6 transmembrane domains and an ATP binding site which shows over 65% of amino acid similarity with the first half of the polypeptide.
Expression
Normally expressed at secretory surface of a number of tissues, including biliary canaliculi, proximal tubules of the kidney, intestinal and colonic epithelium; hematopoietic stem cells express high levels of Pglycoprotein; overexpressed in many multidrug resistant cell lines and in tumour cells resistant to chemotherapy.
Localisation
Mainly at the cell membrane, with a secondary localisation at the Golgi apparatus.
Function
The P-glycoprotein is an energy-dependent efflux pump involved in extrusion of many types of lypophilic coumpounds; it may acts in normal tissues as a protective mechanism against noxious xenobiotics and as a transporter of endogenous substrates; in tumour cells, the drug efflux pump results in a decrease in intracellular drug concentration.
Homology
Closely related gene to MDR3 (also called PGY3), located at the same chromosomal site but not implicated in multidrug resistance; there are 3 murine homolog genes (mdr1, mdr2, mdr3) out of which only 2 (mdr1 and mdr3) are involved in multidrug resistance; member of a large superfamily of transmembrane transporter proteins named ATP Binding Cassette (ABC) transporters or Traffic ATPases; structural homology with other ABC transporter proteins (CFTR, MRP).
Implicated in
Tumour cells resistance
Disease
Tumour cells resistance to a wide variety of antineoplasic agents: doxorubicin, daunorubicin, vinblastine, vincristine, colchicine, actinomycine D, etoposide, tenoposide, mitoxantrone, homoharringtonine; this phenomenon is named 'multidrug resistance' (MDR); P-glycoprotein is the main protein responsible for the MDR phenotype;
ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1)
Viguié F Atlas Genet Cytogenet Oncol Haematol. 1998; 2(2) however, other agents may be involved in MDR, independently or in association with P-glycoprotein: "multidrug resistant associated protein" (MRP), "lung resistance protein" (LRP), 'anthracycline associated resistance protein" (ARX).
Leukemias
Disease
In leukemia, MDR1 overexpression is observed in patients with a lower complete remission rate and with a shortening of overall survival; frequently associated with intermediate and poor prognosis karyotype; in ANLL, approximately 50% of patients are MDR positive at diagnosis (range 22-70%) and the MDR phenotype is more frequently observed in CD34+ leukemias; in ALL, the average number of MDRpositive cases is 22% at diagnosis.
Tumour cell lines
Note
In numerous continuous tumour cell lines which acquired experimentally a MDR phenotype when cultured with progressively increasing drug concentration, the acquisition of MDR was associated with hyperexpression of P-glycoprotein; for the higher levels of expression, southern blots revealed an increase in the number of copies of the MDR1 gene per cell.
Cytogenetics
The genomic amplification of MDR1 appears as extrachromosomic 'double-minute chromosomes' (DM) or intrachromosomic 'homogeneous staining regions' (HSR). Oncogenesis Amplification.
